TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16617767

Group type: EXPERIMENTAL
Intervention: Titanium cylinder-design cage
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Carbon box-design cage
Number of subjects: 46
Study: 17638141

Group type: EXPERIMENTAL
Intervention: 6-minute walk test
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Fugl-Meyer lower-limb motor score and Berg Balance score
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Pulse and blood pressure pre- and posttesting
Number of subjects: 72
Study: 11332356

Group type: EXPERIMENTAL
Intervention: Antioxidants (vitamins C and E) and Calcium Channel Blockers (nimodipine)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no antioxidants or calcium channel blockers)
Number of subjects: 120
Study: 8935814

Group type: EXPERIMENTAL
Intervention: Clozapine withdrawal with addition of neuroleptic
Number of subjects: 83

Group type: COMPARATOR
Intervention: Clozapine withdrawal without addition of neuroleptic
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Clozapine withdrawal with addition of cyproheptadine
Number of subjects: 83

Group type: COMPARATOR
Intervention: Naturalistic discontinuation of clozapine in neuroleptic‐resistant patients
Number of subjects: 83
Study: 1387844

Group type: EXPERIMENTAL
Intervention: Fungoid Tincture
Number of subjects: 10

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 10
Study: 2998785

Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 5

Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 5
Study: 30834652

Group type: EXPERIMENTAL
Intervention: Blood flow rate reduction of 100 mL/min to a minimum of 300 mL/min
Number of subjects: 102

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 102
Study: 29080069

Group type: EXPERIMENTAL
Intervention: 5-Aminosalicylic Acid (5-ASA) 500 mg capsules, four times daily for 6 weeks
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 5-Aminosalicylic Acid (5-ASA)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 27426231

Group type: EXPERIMENTAL
Intervention: LFCN block with 8 ml of 0.75% ropivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: LFCN block with 8 ml of saline
Number of subjects: 60
Study: 25242806

Group type: EXPERIMENTAL
Intervention: NEUROvitalis (structured training)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Mentally fit (unstructured training)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 65
Study: 22824201

Group type: EXPERIMENTAL
Intervention: 10 mg everolimus daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5 mg everolimus daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20731976

Group type: EXPERIMENTAL
Intervention: Brief motivational intervention
Number of subjects: 957

Group type: EXPERIMENTAL
Intervention: Case management intervention
Number of subjects: 957

Group type: COMPARATOR
Intervention: Referral brochure
Number of subjects: 957
Study: 18056556

Group type: EXPERIMENTAL
Intervention: Enhanced communication intervention (five 2 1/2‐hour sessions)
Number of subjects: 1115

Group type: EXPERIMENTAL
Intervention: Single‐session communication intervention (one 2 1/2‐hour session)
Number of subjects: 1115

Group type: COMPARATOR
Intervention: General health intervention (control, one 2 1/2‐hour session)
Number of subjects: 1115
Study: 16681100

Group type: EXPERIMENTAL
Intervention: Medical and surgical preventive measures for thromboembolic disease
Number of subjects: 0

Group type: COMPARATOR
Intervention: Old concept of thromboembolic prophylaxis
Number of subjects: 0
Study: 11273995

Group type: EXPERIMENTAL
Intervention: Repaired tetralogy of Fallot patients (TOF)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 74
Study: 9385891

Group type: EXPERIMENTAL
Intervention: Treadmill exercise echocardiography
Number of subjects: 85

Group type: COMPARATOR
Intervention: Dobutamine stress echocardiography
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Dobutamine stress echocardiography with atropine
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Dobutamine infusion
Number of subjects: 85

Group type: COMPARATOR
Intervention: Treadmill exercise
Number of subjects: 85
Study: 8205252

Group type: EXPERIMENTAL
Intervention: Oral administration of lipiodol (0.5 ml) 1-3 months before conception (Group A)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Oral administration of lipiodol (0.5 ml) during the first month of pregnancy (Group B)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Oral administration of lipiodol (0.5 ml) during the third month of pregnancy (Group C)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Untreated group (Group D)
Number of subjects: 4
Study: 3297121

Group type: EXPERIMENTAL
Intervention: Amiodarone (200 mg/day)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 2252196

Group type: EXPERIMENTAL
Intervention: Topical 1% hydrocortisone cream
Number of subjects: 40

Group type: COMPARATOR
Intervention: KY jelly
Number of subjects: 40
Study: 1090905

Group type: EXPERIMENTAL
Intervention: Group therapy sessions led by two nurses, twice a week for 20 sessions
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no group therapy)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Group therapy sessions
Number of subjects: 100
Study: 31801563

Group type: EXPERIMENTAL
Intervention: Biannual mass azithromycin distribution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single orally administered dose of azithromycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28489321

Group type: EXPERIMENTAL
Intervention: Nicotine patch (21 mg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 25
Study: 26352697

Group type: EXPERIMENTAL
Intervention: Rural community-based integrated intervention including systematic health education, smoking cessation counseling, and education on management of COPD.
Number of subjects: 1008

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 1008
Study: 23025390

Group type: EXPERIMENTAL
Intervention: 5 g of yellow mustard bran
Number of subjects: 10

Group type: COMPARATOR
Intervention: Potato and leek soup without yellow mustard bran
Number of subjects: 10
Study: 20932157

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) with GaAlAs diode laser, 808 nm wavelength, energy density of 4 J/cm² applied on days 1, 2, and 7 after periodontal treatment
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (non-surgical periodontal therapy without LLLT)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: LLLT group (smokers)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Both groups (LLLT and control)
Number of subjects: 36
Study: 19535691

Group type: EXPERIMENTAL
Intervention: Epsilon-aminocaproic acid (EACA)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 78

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 78
Study: 16926245

Group type: EXPERIMENTAL
Intervention: Testosterone (T) gel therapy, 50 mg/d for 6 months
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (age-matched controls)
Number of subjects: 35
Study: 15624399

Group type: EXPERIMENTAL
Intervention: Surgical treatment of varicocele
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11701677

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone patch plus oral desogestrel (300 microg/d)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone patch plus oral desogestrel (150 microg/d)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone patch plus oral desogestrel (75 microg/d)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone patch plus oral desogestrel (various doses)
Number of subjects: 23
Study: 9385486

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (CIP) 750 mg BID for 10 days
Number of subjects: 743

Group type: COMPARATOR
Intervention: Clarithromycin (CLR) 500 mg BID for 10 days
Number of subjects: 743

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (CIP)
Number of subjects: 743

Group type: COMPARATOR
Intervention: Clarithromycin (CLR)
Number of subjects: 743
Study: 8201718

Group type: EXPERIMENTAL
Intervention: Angioscopically assisted valve lysis and vein branch identification (scope)
Number of subjects: 59

Group type: COMPARATOR
Intervention: No angioscopy (no scope)
Number of subjects: 59
Study: 3034221

Group type: EXPERIMENTAL
Intervention: oral metyrapone tartrate
Number of subjects: 14

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 14
Study: 29903847

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 9340

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9340

Group type: EXPERIMENTAL
Intervention: Combined analysis (liraglutide and placebo)
Number of subjects: 9340
Study: 28646216

Group type: EXPERIMENTAL
Intervention: Naftopidil 75 mg once daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 25310567

Group type: EXPERIMENTAL
Intervention: Image capture method for knee joint-position-sense measurement
Number of subjects: 10

Group type: COMPARATOR
Intervention: Isokinetic dynamometer (IKD) method for knee joint-position-sense measurement
Number of subjects: 10
Study: 23208521

Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine (0.125%) alone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine (0.125%) with fentanyl (2 µg/ml)
Number of subjects: 40
Study: 20955511

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 97

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 97
Study: 19568711

Group type: EXPERIMENTAL
Intervention: Artequick (administered twice in 24 h)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Artekin (administered 4 times in 2 days)
Number of subjects: 103
Study: 16764182

Group type: EXPERIMENTAL
Intervention: Patient-controlled regional anesthesia device (Pain Care 2000; Breg, Inc, Vista, Calif)
Number of subjects: 41
Study: 14769577

Group type: EXPERIMENTAL
Intervention: Total or near-total thyroidectomy (group 1; n = 109)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Bilateral subtotal thyroidectomy (group 2; n = 109)
Number of subjects: 218
Study: 11882452

Group type: EXPERIMENTAL
Intervention: Transmyocardial revascularization with CO(2) laser in addition to medical treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Continued optimal medical treatment
Number of subjects: 100
Study: 9089559

Group type: EXPERIMENTAL
Intervention: Estradiol-releasing vaginal ring with a 100 mg vaginal progesterone suppository (7 days every month)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Transdermal daily dose of 50 micrograms of estradiol with a levonorgestrel-releasing intrauterine device
Number of subjects: 56
Study: 8185744

Group type: EXPERIMENTAL
Intervention: TENS group (n = 19)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (n = 19)
Number of subjects: 38
Study: 3131040

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 100 mg recombinant tissue-type plasminogen activator (rt-PA) over 3 hours
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study: 31277796

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept 2 mg every 4 weeks
Number of subjects: 366

Group type: COMPARATOR
Intervention: Sham injections
Number of subjects: 366
Study: 28007457

Group type: EXPERIMENTAL
Intervention: Vascular-targeted photodynamic therapy (4 mg/kg padeliporfin intravenously over 10 min, laser activation for 22 min 15 s)
Number of subjects: 413

Group type: COMPARATOR
Intervention: Active surveillance
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Vascular-targeted photodynamic therapy
Number of subjects: 413
Study: 24824304

Group type: EXPERIMENTAL
Intervention: Manual root planing with a curette
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Piezoelectric ultrasonic (PU) scraper
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Vertically oscillating ultrasonic (VOU) scraper
Number of subjects: 19

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 19
Study: 24005276

Group type: EXPERIMENTAL
Intervention: Original septal stent with integrated electrode
Number of subjects: 102

Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 102
Study: 21272972

Group type: EXPERIMENTAL
Intervention: 2-mm locking titanium miniplates
Number of subjects: 20

Group type: COMPARATOR
Intervention: 2-mm standard nonlocking titanium miniplates
Number of subjects: 20
Study: 19849726

Group type: EXPERIMENTAL
Intervention: Hibiscus Abelmoschus seed extract (Linefactor)
Number of subjects: 0
Study: 16821183

Group type: EXPERIMENTAL
Intervention: Simplified palpation method
Number of subjects: 72

Group type: COMPARATOR
Intervention: Recommended palpation method
Number of subjects: 72
Study: 12767646

Group type: EXPERIMENTAL
Intervention: Beraprost sodium 40 microg three times a day with meals (n = 385)
Number of subjects: 897

Group type: COMPARATOR
Intervention: Placebo (n = 377)
Number of subjects: 897

Group type: EXPERIMENTAL
Intervention: Beraprost sodium
Number of subjects: 897

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 897
Study: 10831641

Group type: EXPERIMENTAL
Intervention: rhGH (0.2 IU/kg/day subcutaneously)
Number of subjects: 17
Study: 9380445

Group type: EXPERIMENTAL
Intervention: LCP-enriched preterm formula
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard preterm formula
Number of subjects: 30

Group type: COMPARATOR
Intervention: Breast milk
Number of subjects: 30
Study: 1575571

Group type: EXPERIMENTAL
Intervention: Allergen free diet
Number of subjects: 94

Group type: COMPARATOR
Intervention: Allergen restricted diet (containing only lactoproteins and yellow dyes)
Number of subjects: 94
Study: 2857901

Group type: EXPERIMENTAL
Intervention: Intravenous bolus of 100 micrograms human alpha‐ANP
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31488242

Group type: EXPERIMENTAL
Intervention: Evaluative conditioning (EC) procedure using positive social feedback
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Evaluative conditioning (EC) procedure
Number of subjects: 129
Study: 29529938

Group type: EXPERIMENTAL
Intervention: Pleasant stimulus (PS)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Unpleasant stimulus (US)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Neutral stimulus (NS)
Number of subjects: 20
Study: 25895494

Group type: EXPERIMENTAL
Intervention: Family Startup Program (FSP)
Number of subjects: 2500

Group type: COMPARATOR
Intervention: Treatment As Usual (TAU)
Number of subjects: 2500
Study: 24279747

Group type: EXPERIMENTAL
Intervention: Intradialytic progressive exercise training (using an adapted cycle ergometer)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 50
Study: 21544074

Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen 1,000 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous placebo
Number of subjects: 60
Study: 19033545

Group type: EXPERIMENTAL
Intervention: Endurance exercise (EE) for 6 months
Number of subjects: 0
Study: 17288697

Group type: EXPERIMENTAL
Intervention: Inhaled insulin (HIIP; AIR inhaled insulin)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Subcutaneous insulin (regular human insulin or insulin lispro)
Number of subjects: 137
Study: 15337620

Group type: EXPERIMENTAL
Intervention: Standard aspirin and dipyridamole treatment b.i.d. for 2 weeks
Number of subjects: 57

Group type: COMPARATOR
Intervention: Titration with aspirin only in the morning and aspirin and dipyridamole in the evening for 5 days, followed by 9 days of standard aspirin and dipyridamole treatment
Number of subjects: 57
Study: 11405121

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 9519022

Group type: EXPERIMENTAL
Intervention: Benzocaine spray
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 36
Study: 9510219

Group type: EXPERIMENTAL
Intervention: Olanzapine (5-20 mg/d)
Number of subjects: 1996

Group type: COMPARATOR
Intervention: Haloperidol (5-20 mg/d)
Number of subjects: 1996
Study: 1894296

Group type: EXPERIMENTAL
Intervention: 8 mg intravenous oxyfedrine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 6886353

Group type: EXPERIMENTAL
Intervention: 99mTc-labeled solid-phase meal
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Patients with gastric stasis
Number of subjects: 17
Study: 30966835

Group type: EXPERIMENTAL
Intervention: Dexketoprofen
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no dexketoprofen)
Number of subjects: 60
Study: 30726220

Group type: EXPERIMENTAL
Intervention: Recognition of number-one Billboard singles from the last 76 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-selected exposure to each song as measured by its play count on Spotify
Number of subjects: 0
Study: 30198872

Group type: EXPERIMENTAL
Intervention: Rofecoxib (25 mg once daily)
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Naproxen (220 mg twice-daily)
Number of subjects: 351

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 351
Study: 26653681

Group type: EXPERIMENTAL
Intervention: Anticoagulation therapy
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control
Number of subjects: 64
Study: 24120264

Group type: EXPERIMENTAL
Intervention: Biliopancreatic diversion with duodenal switch (BPD‐DS) surgery
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (severely obese without surgery)
Number of subjects: 73
Study: 22260859

Group type: EXPERIMENTAL
Intervention: 2 g of fish oil (1.1 g marine n‐3 PUFA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 2 g of olive oil (control)
Number of subjects: 50
Study: 20629927

Group type: EXPERIMENTAL
Intervention: Kangaroo holding
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Blanket holding
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (brief social visits, no holding constraints)
Number of subjects: 65
Study: 17896065

Group type: EXPERIMENTAL
Intervention: Major trauma (involving perineal muscles or requiring suturing)
Number of subjects: 444

Group type: COMPARATOR
Intervention: Intact delivery (no trauma)
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: Minor trauma
Number of subjects: 444
Study: 15372199

Group type: EXPERIMENTAL
Intervention: Lidocaine injection
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A) injection
Number of subjects: 29

Group type: COMPARATOR
Intervention: Dry needling
Number of subjects: 29
Study: 11920411

Group type: EXPERIMENTAL
Intervention: 30 mg of cevimeline 3 times daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 15 mg of cevimeline 3 times daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9823079

Group type: EXPERIMENTAL
Intervention: Oscillating/rotating power toothbrush (Braun Oral‐B Ultra Plaque Remover‐D9)
Number of subjects: 62

Group type: COMPARATOR
Intervention: High frequency toothbrush (sonicare)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both toothbrushes
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: D9 toothbrush
Number of subjects: 62
Study: 7967427

Group type: EXPERIMENTAL
Intervention: 12 Gy fractionated total body irradiation (FTBI) and 2 (or 3) cytotoxic drugs (group A, n = 19)
Number of subjects: 28

Group type: COMPARATOR
Intervention: 3 cytotoxic drugs (group B, n = 9)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: FTBI-containing regimen
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Overall survival at day +100
Number of subjects: 28
Study: 3382233

Group type: EXPERIMENTAL
Intervention: Lentinan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MMC and FT(MF) with Lentinan
Number of subjects: 0

Group type: COMPARATOR
Intervention: MMC and FT(MF) without Lentinan
Number of subjects: 0
Study: 29226957

Group type: EXPERIMENTAL
Intervention: Focused cardiac ultrasound before surgery
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no ultrasound)
Number of subjects: 100
Study: 28920458

Group type: EXPERIMENTAL
Intervention: Nordic walking (NW)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional walking training (WT)
Number of subjects: 30
Study: 25070546

Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel (wPxl; 80 mg/m(2)/week ×6 with 2‐week break) plus saracatinib (S; 175 mg o.d.)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Weekly paclitaxel (wPxl; 80 mg/m(2)/week ×6 with 2‐week break) plus placebo (P)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Both groups (wPxl + S and wPxl + P) with taxane interval ≥6 months/no prior taxane
Number of subjects: 107
Study: 23347605

Group type: COMPARATOR
Intervention: Clomiphene citrate 100mg daily for 5 days
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cimicifuga racimosa 20mg daily for 10 days
Number of subjects: 100
Study: 20399668

Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 17440520

Group type: EXPERIMENTAL
Intervention: Probiotic yoghurt supplement containing L. acidophilus 74-2 and B. lactis 420 (300 g/day)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo product
Number of subjects: 26
Study: 17242812

Group type: EXPERIMENTAL
Intervention: Dopaminergic agents, anticonvulsants, opioids, benzodiazepines, zolpidem, entacapone, ketamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Iron
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gabapentin and L-dopa (sustained release formulation)
Number of subjects: 0
Study: 12527491

Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98

Group type: COMPARATOR
Intervention: EMLA cream vs Placebo
Number of subjects: 98
Study: 10212103

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (500 microg twice daily) for four weeks
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 8729126

Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids
Number of subjects: 0

Group type: COMPARATOR
Intervention: steroids and other immunosuppressive agents (e.g., cyclosporin A)
Number of subjects: 0
Study: 1422714

Group type: EXPERIMENTAL
Intervention: 1 per cent lignocaine (n = 19)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Normal saline (n = 21)
Number of subjects: 34